Skip to main content
Premium Trial:

Request an Annual Quote

Inpharmatica Moves Into Japan with Daiichi Deal

NEW YORK, July 8-Daiichi Pharmaceuticals has arranged a nonexclusive subscription to Inpharmatica's Biopendium protein database, Inpharmatica said yesterday.


The specific financial conditions of the agreement were not disclosed.


Biopendium includes protein sequences and structures, as well as tools to predict protein/ligand interactions and compare sequence patterns. It is designed for target discovery and lead compound identification.


Daiichi is Inpharmatica's first Japanese client, joining subscribers such as Pfizer and Genentech.


Inpharmatica is based in London.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.